Regulatory
FDA Approves AbbVie’s Juvmo, a New Kind of Once-Daily Parkinson’s Pill
Tavapadon targets a narrower set of dopamine receptors than older drugs, aiming to ease movement symptoms with fewer of the side effects that make dopamine agonists hard to tolerate.